search
Back to results

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Primary Purpose

Influenza A

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
MHAA4549A
Placebo
Sponsored by
Genentech, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Influenza A

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Otherwise healthy participants
  • Positive test for influenza A infection
  • No more than 72 hours elapsed between onset of influenza-like illness and start of study drug
  • Presence of at least one moderate or severe constitutional symptom such as headache, myalgia, fever, chills, fatigue, anorexia, or nausea PLUS one moderate or severe respiratory symptom such as cough, sore throat, or rhinorrhea
  • For women of childbearing potential: negative pregnancy test and agreement to use acceptable contraceptive methods for at least 120 days after study drug administration
  • For men: agreement to use acceptable contraceptive methods for at least 30 days after study drug administration

Exclusion Criteria:

  • Creatinine clearance less than or equal to (</=) 80 milliliters per minute (mL/min)
  • Any significant medical conditions or laboratory abnormalities
  • Clinical signs and symptoms consistent with otitis, bronchitis, sinusitis, or pneumonia or active bacterial infection
  • Use of antiviral therapy in the period from onset of influenza-like illness and prior to enrollment
  • Pregnancy at Screening or is currently pregnant or breastfeeding
  • Investigational therapy within 30 days or 5 half-lives prior to start of study drug, whichever is greater
  • Prior anti-influenza monoclonal antibody use
  • Receipt of a nasal influenza A vaccine within 14 days prior to Screening
  • Positive test for influenza B or influenza A+B within 2 weeks prior to study drug
  • History of significant tobacco use or drug/alcohol abuse
  • Chronic use of oral or inhaled corticosteroids within 30 days prior to Screening
  • Autoimmune disease, known immunodeficiency of any cause, or use of immunosuppressive medications
  • History of any chronic respiratory condition
  • Human immunodeficiency virus (HIV) with cluster of differentiation (CD) 4 count </= 200 cells per milliliter (cells/mL) in the past 12 months
  • Serious infection requiring oral or IV antibiotics within 14 days prior to Screening

Sites / Locations

  • North Alabama Research Center LLC
  • WCCT Global, LLC
  • Lalla-Reddy Medical Corporation
  • IMMUNOe Research Centers
  • Integrity Clinical Research
  • Riverside Clinical Research
  • Sarkis Clinical Trials
  • The Community Research Of South Florida
  • Innovative Clinical Research, Inc.
  • South Florida Research Center, Inc.
  • Oceane7 Clinical Research
  • Central Florida Internists
  • Tampa General Hospital
  • Advanced Research Institute, Inc.
  • Cotton O'Neil Clinical Research Center
  • Professional Research Network of Kansas
  • Heartland Research Associates
  • Kentucky Lung Clinic
  • MedPharmics
  • Acadiana Medicine Clinic
  • Anne Arundel Medical Center; Anne Arundel Health System
  • UMASS Memorial Medical Center
  • Detroit Medical Center
  • Sinai Grace Hospital
  • William Beaumont Hospital
  • Barnes Jewish Hospital
  • Mercury Street Medical Group
  • Barrett Clinic, P.C.
  • Global Medical Institutes, LLC
  • Wake Research Associates
  • Center For Medical Research LLC
  • Emergency MD
  • HCCA Clinical Research Solutions
  • Clinical Research Solutions PC
  • Clinical Research Solutions, LLC
  • University of Texas Medical Branch at Galveston
  • Centex Studies
  • Centex Studies
  • Manna Research Vancouver
  • Moncton Hospital
  • Manna Research
  • Q and T Research
  • inVentiv Health Clinique
  • Hallym University Sacred Heart Hospital
  • Soon Chun Hyang University Hospital Bucheon
  • Gachon University Gil Hospital
  • Korea University Anam Hospital
  • Hallym University Kangnam Sacred Heart Hospital
  • Korea University Guro Hospital
  • Wonju Christian Hospital
  • Henderson Medical Centre
  • Optimal Clinical Trials
  • RMC Medical Research Ltd
  • Tauranga Hospital
  • Johese Clinical Research
  • Durban International Clinical Research Site
  • Vawda Z Private Practice
  • Dr Peter John Sebastian; Dr PJ Sebastian
  • Into Research; Life Groenkloof Hospital Medical Centre
  • Worthwhile Clinical Trials
  • Newtown Clinical Research
  • Clinresco Centres (Pty) Ltd
  • Peermed Clinical Trial Centre
  • Klerksdorp /Tshepong Hospital Complex
  • DJW Navorsing
  • I Engelbrecht Research
  • Syzygy Clinical Research; Unit 3 to 7
  • Jongaie Research
  • Queenswood CTC
  • Wits Clinical Research
  • Welkom Clinical Trial Centre
  • Hospital Mutua de Terrassa; Servicio de Oncologia
  • Hospital Universitario Son Espases
  • Hospital San Pedro
  • Hospital de Galdakao
  • Hospital del Mar
  • Hospital Clinic de Barcelona
  • Surrey Clinical Research Centre; University of Surrey
  • Barts and the London NHS Trust.
  • The James Cook University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

MHAA4549A 3600 milligrams (mg)

MHAA4549A 8400 mg

Placebo

Arm Description

Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.

Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.

Participants will receive single-dose placebo by IV administration.

Outcomes

Primary Outcome Measures

Percentage of Participants With Adverse Events (AEs)
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.

Secondary Outcome Measures

Percentage of Participants Requiring Hospitalization for Influenza-Related Complications
Duration of Hospitalization for Influenza-Related Complications
Percentage of Participants Requiring Antibiotics for Secondary Bacterial Respiratory Infections
Participants with antibiotic usage for secondary bacterial respiratory infections were identified by counting participants with AEs containing the terms, "pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory."
Percentage of Participants With Complications of Influenza
Participants with complications of influenza were identified by counting participants with AEs containing the terms, "pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory."
Percentage of Participants With Influenza A Relapse/Reinfection
Area Under the Concentration-Time Curve (AUC) of MHAA4549A
The AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. AUC was measured in micrograms times hours per milliliter (mcg*h/mL).
Maximum Serum Concentration (Cmax) of MHAA4549A
Time to Alleviation of Symptoms of Influenza A Infection
Time to alleviation of all 7 symptoms (i.e., nasal congestion, sore throat, cough, aches, fatigue, headaches, chills/sweats) was assessed using a rating scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe) for each symptom. The outcome was defined in two ways: time to a total symptom score of <=1 and time to a total symptom score of <=7. Resolution had to be maintained for 24 hours without use of symptom relief medications. For participants who were enrolled with mild symptoms, the symptom score had to be reduced by one point during the study duration.
Percentage of Participants With Influenza-Related Deaths

Full Information

First Posted
December 3, 2015
Last Updated
December 14, 2018
Sponsor
Genentech, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02623322
Brief Title
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
Official Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
October 12, 2016 (Actual)
Primary Completion Date
November 13, 2017 (Actual)
Study Completion Date
November 13, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Genentech, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety and tolerability, efficacy, and pharmacokinetics of MHAA4549A.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza A

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
124 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MHAA4549A 3600 milligrams (mg)
Arm Type
Experimental
Arm Description
Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.
Arm Title
MHAA4549A 8400 mg
Arm Type
Experimental
Arm Description
Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive single-dose placebo by IV administration.
Intervention Type
Drug
Intervention Name(s)
MHAA4549A
Intervention Description
MHAA4549A will be administered as a single dose by IV administration.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be administered as a single dose by IV administration.
Primary Outcome Measure Information:
Title
Percentage of Participants With Adverse Events (AEs)
Description
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.
Time Frame
Baseline to Day 100
Secondary Outcome Measure Information:
Title
Percentage of Participants Requiring Hospitalization for Influenza-Related Complications
Time Frame
Baseline to Day 100
Title
Duration of Hospitalization for Influenza-Related Complications
Time Frame
Baseline to Day 100
Title
Percentage of Participants Requiring Antibiotics for Secondary Bacterial Respiratory Infections
Description
Participants with antibiotic usage for secondary bacterial respiratory infections were identified by counting participants with AEs containing the terms, "pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory."
Time Frame
Baseline to Day 100
Title
Percentage of Participants With Complications of Influenza
Description
Participants with complications of influenza were identified by counting participants with AEs containing the terms, "pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory."
Time Frame
Baseline to Day 100
Title
Percentage of Participants With Influenza A Relapse/Reinfection
Time Frame
Baseline to Day 100
Title
Area Under the Concentration-Time Curve (AUC) of MHAA4549A
Description
The AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. AUC was measured in micrograms times hours per milliliter (mcg*h/mL).
Time Frame
Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)
Title
Maximum Serum Concentration (Cmax) of MHAA4549A
Time Frame
Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)
Title
Time to Alleviation of Symptoms of Influenza A Infection
Description
Time to alleviation of all 7 symptoms (i.e., nasal congestion, sore throat, cough, aches, fatigue, headaches, chills/sweats) was assessed using a rating scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe) for each symptom. The outcome was defined in two ways: time to a total symptom score of <=1 and time to a total symptom score of <=7. Resolution had to be maintained for 24 hours without use of symptom relief medications. For participants who were enrolled with mild symptoms, the symptom score had to be reduced by one point during the study duration.
Time Frame
Baseline to Day 14
Title
Percentage of Participants With Influenza-Related Deaths
Time Frame
Baseline to Day 100

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Otherwise healthy participants Positive test for influenza A infection No more than 72 hours elapsed between onset of influenza-like illness and start of study drug Presence of at least one moderate or severe constitutional symptom such as headache, myalgia, fever, chills, fatigue, anorexia, or nausea PLUS one moderate or severe respiratory symptom such as cough, sore throat, or rhinorrhea For women of childbearing potential: negative pregnancy test and agreement to use acceptable contraceptive methods for at least 120 days after study drug administration For men: agreement to use acceptable contraceptive methods for at least 30 days after study drug administration Exclusion Criteria: Creatinine clearance less than or equal to (</=) 80 milliliters per minute (mL/min) Any significant medical conditions or laboratory abnormalities Clinical signs and symptoms consistent with otitis, bronchitis, sinusitis, or pneumonia or active bacterial infection Use of antiviral therapy in the period from onset of influenza-like illness and prior to enrollment Pregnancy at Screening or is currently pregnant or breastfeeding Investigational therapy within 30 days or 5 half-lives prior to start of study drug, whichever is greater Prior anti-influenza monoclonal antibody use Receipt of a nasal influenza A vaccine within 14 days prior to Screening Positive test for influenza B or influenza A+B within 2 weeks prior to study drug History of significant tobacco use or drug/alcohol abuse Chronic use of oral or inhaled corticosteroids within 30 days prior to Screening Autoimmune disease, known immunodeficiency of any cause, or use of immunosuppressive medications History of any chronic respiratory condition Human immunodeficiency virus (HIV) with cluster of differentiation (CD) 4 count </= 200 cells per milliliter (cells/mL) in the past 12 months Serious infection requiring oral or IV antibiotics within 14 days prior to Screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
North Alabama Research Center LLC
City
Athens
State/Province
Alabama
ZIP/Postal Code
35611
Country
United States
Facility Name
WCCT Global, LLC
City
Costa Mesa
State/Province
California
ZIP/Postal Code
92626
Country
United States
Facility Name
Lalla-Reddy Medical Corporation
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
IMMUNOe Research Centers
City
Centennial
State/Province
Colorado
ZIP/Postal Code
80112
Country
United States
Facility Name
Integrity Clinical Research
City
Doral
State/Province
Florida
ZIP/Postal Code
33166
Country
United States
Facility Name
Riverside Clinical Research
City
Edgewater
State/Province
Florida
ZIP/Postal Code
32132
Country
United States
Facility Name
Sarkis Clinical Trials
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32607
Country
United States
Facility Name
The Community Research Of South Florida
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
Innovative Clinical Research, Inc.
City
Lauderhill
State/Province
Florida
ZIP/Postal Code
33319
Country
United States
Facility Name
South Florida Research Center, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Oceane7 Clinical Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
Central Florida Internists
City
Saint Cloud
State/Province
Florida
ZIP/Postal Code
34769
Country
United States
Facility Name
Tampa General Hospital
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Advanced Research Institute, Inc.
City
Trinity
State/Province
Florida
ZIP/Postal Code
34655
Country
United States
Facility Name
Cotton O'Neil Clinical Research Center
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Professional Research Network of Kansas
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67205
Country
United States
Facility Name
Heartland Research Associates
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67207
Country
United States
Facility Name
Kentucky Lung Clinic
City
Hazard
State/Province
Kentucky
ZIP/Postal Code
41701
Country
United States
Facility Name
MedPharmics
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Acadiana Medicine Clinic
City
Opelousas
State/Province
Louisiana
ZIP/Postal Code
70570
Country
United States
Facility Name
Anne Arundel Medical Center; Anne Arundel Health System
City
Annapolis
State/Province
Maryland
ZIP/Postal Code
21401
Country
United States
Facility Name
UMASS Memorial Medical Center
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Facility Name
Detroit Medical Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Sinai Grace Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48235
Country
United States
Facility Name
William Beaumont Hospital
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Facility Name
Barnes Jewish Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63108
Country
United States
Facility Name
Mercury Street Medical Group
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
Facility Name
Barrett Clinic, P.C.
City
La Vista
State/Province
Nebraska
ZIP/Postal Code
68128
Country
United States
Facility Name
Global Medical Institutes, LLC
City
Princeton
State/Province
New Jersey
ZIP/Postal Code
08540
Country
United States
Facility Name
Wake Research Associates
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27612
Country
United States
Facility Name
Center For Medical Research LLC
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02908
Country
United States
Facility Name
Emergency MD
City
Boiling Springs
State/Province
South Carolina
ZIP/Postal Code
29316
Country
United States
Facility Name
HCCA Clinical Research Solutions
City
Franklin
State/Province
Tennessee
ZIP/Postal Code
37067
Country
United States
Facility Name
Clinical Research Solutions PC
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37920
Country
United States
Facility Name
Clinical Research Solutions, LLC
City
Smyrna
State/Province
Tennessee
ZIP/Postal Code
37167
Country
United States
Facility Name
University of Texas Medical Branch at Galveston
City
Galveston
State/Province
Texas
ZIP/Postal Code
77555
Country
United States
Facility Name
Centex Studies
City
Houston
State/Province
Texas
ZIP/Postal Code
77058
Country
United States
Facility Name
Centex Studies
City
Pharr
State/Province
Texas
Country
United States
Facility Name
Manna Research Vancouver
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6J 1S3
Country
Canada
Facility Name
Moncton Hospital
City
Moncton
State/Province
New Brunswick
ZIP/Postal Code
E1C 6Z8
Country
Canada
Facility Name
Manna Research
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M9W 4L6
Country
Canada
Facility Name
Q and T Research
City
Gatineau
State/Province
Quebec
ZIP/Postal Code
J8Y 6S9
Country
Canada
Facility Name
inVentiv Health Clinique
City
Quebec
ZIP/Postal Code
G1P 0A2
Country
Canada
Facility Name
Hallym University Sacred Heart Hospital
City
Anyang-si
ZIP/Postal Code
14068
Country
Korea, Republic of
Facility Name
Soon Chun Hyang University Hospital Bucheon
City
Bucheon-si,
ZIP/Postal Code
420-767
Country
Korea, Republic of
Facility Name
Gachon University Gil Hospital
City
Incheon
Country
Korea, Republic of
Facility Name
Korea University Anam Hospital
City
Seoul
ZIP/Postal Code
02841
Country
Korea, Republic of
Facility Name
Hallym University Kangnam Sacred Heart Hospital
City
Seoul
ZIP/Postal Code
07441
Country
Korea, Republic of
Facility Name
Korea University Guro Hospital
City
Seoul
ZIP/Postal Code
08308
Country
Korea, Republic of
Facility Name
Wonju Christian Hospital
City
Wonju
ZIP/Postal Code
220-701
Country
Korea, Republic of
Facility Name
Henderson Medical Centre
City
Auckland
ZIP/Postal Code
0612
Country
New Zealand
Facility Name
Optimal Clinical Trials
City
Auckland
ZIP/Postal Code
1010
Country
New Zealand
Facility Name
RMC Medical Research Ltd
City
Dunedin
Country
New Zealand
Facility Name
Tauranga Hospital
City
Tauranga
ZIP/Postal Code
3143
Country
New Zealand
Facility Name
Johese Clinical Research
City
Centurion
ZIP/Postal Code
1692
Country
South Africa
Facility Name
Durban International Clinical Research Site
City
Durban
ZIP/Postal Code
4052
Country
South Africa
Facility Name
Vawda Z Private Practice
City
Durban
ZIP/Postal Code
4091
Country
South Africa
Facility Name
Dr Peter John Sebastian; Dr PJ Sebastian
City
Durban
ZIP/Postal Code
4092
Country
South Africa
Facility Name
Into Research; Life Groenkloof Hospital Medical Centre
City
Groenkloof
ZIP/Postal Code
0181
Country
South Africa
Facility Name
Worthwhile Clinical Trials
City
Johannesburg
ZIP/Postal Code
1500
Country
South Africa
Facility Name
Newtown Clinical Research
City
Johannesburg
ZIP/Postal Code
2113
Country
South Africa
Facility Name
Clinresco Centres (Pty) Ltd
City
Kempton Park
ZIP/Postal Code
1619
Country
South Africa
Facility Name
Peermed Clinical Trial Centre
City
Kempton Park
ZIP/Postal Code
1619
Country
South Africa
Facility Name
Klerksdorp /Tshepong Hospital Complex
City
Klerksdorp
ZIP/Postal Code
2574
Country
South Africa
Facility Name
DJW Navorsing
City
Krugersdorp
ZIP/Postal Code
1739
Country
South Africa
Facility Name
I Engelbrecht Research
City
Lyttleton
ZIP/Postal Code
0157
Country
South Africa
Facility Name
Syzygy Clinical Research; Unit 3 to 7
City
Pretoria Gauteng Province
ZIP/Postal Code
0087
Country
South Africa
Facility Name
Jongaie Research
City
Pretoria-West
ZIP/Postal Code
0183
Country
South Africa
Facility Name
Queenswood CTC
City
Queenswood
ZIP/Postal Code
0121
Country
South Africa
Facility Name
Wits Clinical Research
City
Soweto
ZIP/Postal Code
2013
Country
South Africa
Facility Name
Welkom Clinical Trial Centre
City
Welkom
ZIP/Postal Code
9460
Country
South Africa
Facility Name
Hospital Mutua de Terrassa; Servicio de Oncologia
City
Terrassa
State/Province
Barcelona
ZIP/Postal Code
08221
Country
Spain
Facility Name
Hospital Universitario Son Espases
City
Palma de Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07010
Country
Spain
Facility Name
Hospital San Pedro
City
Logroño
State/Province
LA Rioja
ZIP/Postal Code
26006
Country
Spain
Facility Name
Hospital de Galdakao
City
Galdacao
State/Province
Vizcaya
ZIP/Postal Code
48960
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Surrey Clinical Research Centre; University of Surrey
City
Guildford
ZIP/Postal Code
GU2 7XP
Country
United Kingdom
Facility Name
Barts and the London NHS Trust.
City
London
ZIP/Postal Code
EC1A 7BE
Country
United Kingdom
Facility Name
The James Cook University Hospital
City
Middlesborough
ZIP/Postal Code
TS4 3BW
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

We'll reach out to this number within 24 hrs